Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target

$403.30 -5.55 (-1.36%)

Closing price 10/3/2025 04:00 PM Eastern

Extended Trading

$403.82 +0.51 (+0.13%)

As of 10/3/2025 07:59 PM Eastern

Compare

Vertex Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Moderate Buy

Based on 29 Analyst Ratings

Sell
0

Hold
12

Buy
17

Based on 29 Wall Street analysts who have issued ratings for Vertex Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 29 analysts, 12 have given a hold rating, 16 have given a buy rating, and 1 has given a strong buy rating for VRTX.

Consensus Price Target

$493.81
22.44% Upside

According to the 29 analysts' twelve-month price targets for Vertex Pharmaceuticals, the average price target is $493.81. The highest price target for VRTX is $575.00, while the lowest price target for VRTX is $405.00. The average price target represents a forecasted upside of 22.44% from the current price of $403.30.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for VRTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Vertex Pharmaceuticals and its competitors.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VRTX Analyst Ratings Over Time

Type	Current Forecast 10/4/24 to 10/4/25	1 Month Ago 9/4/24 to 9/4/25	3 Months Ago 7/6/24 to 7/6/25	1 Year Ago 10/5/23 to 10/4/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	16 Buy rating(s)	13 Buy rating(s)	13 Buy rating(s)	16 Buy rating(s)
Hold	12 Hold rating(s)	13 Hold rating(s)	14 Hold rating(s)	7 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	3 Sell rating(s)
Consensus Price Target	$493.81	$497.10	$511.62	$486.95
Forecasted Upside	22.44% Upside	25.24% Upside	12.53% Upside	6.95% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

VRTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

VRTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Vertex Pharmaceuticals Stock vs. The Competition

Type	Vertex Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.62	2.69	2.52
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	22.44% Upside	1,376.64% Upside	10.49% Upside
News Sentiment Rating	Positive News See Recent VRTX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
10/2/2025	Citigroup 3 of 5 stars	Geoff Meacham Not Rated	Boost Target	Buy	$550.00 ➝ $575.00	+40.80%
9/27/2025	Weiss Ratings 0 of 5 stars		Reiterated Rating	Hold (C+)
9/25/2025	Leerink Partnrs 1 of 5 stars		Upgrade	Hold ➝ Strong-Buy
9/25/2025	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Risinger Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$458.00 ➝ $456.00	+21.08%
9/11/2025	Evercore ISI Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Liisa Bayko Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$510.00 ➝ $475.00	+21.55%
9/2/2025	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Danielle Brill Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Market Perform
8/6/2025	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Whitney Ijem Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Hold	$424.00 ➝ $411.00	+6.45%
8/6/2025	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Debjit Chattopadhyay Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$558.00 ➝ $546.00	+40.91%
8/6/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mohit Bansal Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$460.00	+22.67%
8/5/2025	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Greg Harrison Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Sector Perform	$442.00 ➝ $438.00	+11.47%
Get the Latest News and Ratings for VRTX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
8/5/2025	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joon Lee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Buy	$520.00 ➝ $490.00	+24.70%
8/5/2025	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Abrahams Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Sector Perform	$430.00 ➝ $405.00	+3.86%
8/5/2025	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Colin Bristow Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Buy	$582.00 ➝ $553.00	+37.88%
8/5/2025	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Evan Seigerman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Outperform	$557.00 ➝ $530.00	+12.22%
8/5/2025	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Carter Gould Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$535.00 ➝ $485.00	+2.70%
8/5/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Paul Matteis Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Hold	$494.00 ➝ $455.00	-3.66%
8/5/2025	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andrew S. Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$550.00 ➝ $478.00	+1.21%
8/5/2025	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Harrison Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Equal Weight	$460.00 ➝ $439.00	-7.04%
7/14/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jessica Fye Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$515.00 ➝ $517.00	+9.43%
5/23/2025	Erste Group Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	H. Engel Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/7/2025	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	A. Chen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Outperform ➝ Peer Perform
5/6/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Buy
5/6/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
5/6/2025	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joseph Stringer Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Hold
3/31/2025	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ying Huang Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$555.00 ➝ $567.00	+15.08%
2/11/2025	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gena Wang Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$435.00 ➝ $467.00	+1.35%
1/27/2025	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Christopher Raymond Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$535.00 ➝ $533.00	+20.72%
12/19/2024	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
12/9/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Buy	$500.00 ➝ $550.00	+19.02%
7/23/2024	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$450.00 ➝ $500.00	+1.60%
6/27/2024	Redburn Atlantic Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	S. Chesney Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy	$545.00	+14.98%
6/17/2024	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$465.00 ➝ $550.00	+15.48%
2/2/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
1/31/2024	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Neutral ➝ Underperform	$325.00	-25.27%
1/31/2024	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Hold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 01:59 AM ET.

Should I Buy Vertex Pharmaceuticals Stock? VRTX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, October 3, 2025. Please send any questions or comments about these Vertex Pharmaceuticals pros and cons to contact@marketbeat.com.

Vertex Pharmaceuticals
Bull Case

Here are some ways that investors could benefit from investing in Vertex Pharmaceuticals Incorporated:

The company recently reported strong earnings, with an EPS of $4.52, exceeding expectations, indicating robust financial health and operational efficiency.
Vertex Pharmaceuticals Incorporated has shown significant revenue growth, with a year-over-year increase of 11.3%, suggesting a strong demand for its products.
Analysts have a consensus rating of "Moderate Buy" for the stock, with an average price target of approximately $493.81, indicating potential for price appreciation.
The current stock price is around $408.25, which may present a buying opportunity for investors looking to enter at a favorable level.
Recent analyst upgrades, including a target price increase from Citigroup to $575.00, reflect positive sentiment and confidence in the company's future performance.

Vertex Pharmaceuticals
Bear Case

Investors should be bearish about investing in Vertex Pharmaceuticals Incorporated for these reasons:

Despite recent growth, the stock has experienced volatility, with a 52-week range showing a low of $362.50 and a high of $519.88, indicating potential risks associated with price fluctuations.
Some analysts have downgraded their price targets, suggesting a cautious outlook on the stock's short-term performance.
The company faces competition in the biotechnology sector, which could impact its market share and profitability in the future.
Insider ownership is relatively low at 0.20%, which may raise concerns about alignment between management and shareholder interests.
The pharmaceutical industry is subject to regulatory scrutiny, and any adverse regulatory changes could negatively affect Vertex Pharmaceuticals Incorporated's operations and stock performance.

VRTX Forecast - Frequently Asked Questions

: According to the research reports of 29 Wall Street equities research analysts, the average twelve-month stock price forecast for Vertex Pharmaceuticals is $493.81, with a high forecast of $575.00 and a low forecast of $405.00.
: 29 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last twelve months. There are currently 12 hold ratings, 16 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" VRTX shares.
: According to analysts, Vertex Pharmaceuticals's stock has a predicted upside of 22.44% based on their 12-month stock forecasts.
: Over the previous 90 days, Vertex Pharmaceuticals's stock had 3 upgrades by analysts.
: Vertex Pharmaceuticals has been rated by research analysts at BMO Capital Markets, Canaccord Genuity Group, Cantor Fitzgerald, Citigroup, Evercore ISI, Guggenheim, HC Wainwright, JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, Morgan Stanley, Raymond James Financial, Royal Bank Of Canada, Scotiabank, Stifel Nicolaus, Truist Financial, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.
: Analysts like Vertex Pharmaceuticals more than other "medical" companies. The consensus rating for Vertex Pharmaceuticals is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how VRTX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:VRTX) was last updated on 10/4/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target

Vertex Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Consensus Price Target

VRTX Analyst Ratings Over Time

VRTX Analyst Recommendations By Month

VRTX Price Targets by Month

Vertex Pharmaceuticals Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Vertex Pharmaceuticals Stock? VRTX Pros and Cons Explained

Vertex Pharmaceuticals
Bull Case

Vertex Pharmaceuticals
Bear Case

VRTX Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target

Vertex Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Consensus Price Target

VRTX Analyst Ratings Over Time

VRTX Analyst Recommendations By Month

VRTX Price Targets by Month

Vertex Pharmaceuticals Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Vertex Pharmaceuticals Stock? VRTX Pros and Cons Explained

Vertex Pharmaceuticals Bull Case

Vertex Pharmaceuticals Bear Case

VRTX Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Vertex Pharmaceuticals
Bull Case

Vertex Pharmaceuticals
Bear Case